Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 1 · 14.3%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 0 · 0%

All strokes and systemic embolic events · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in all strokes and systemic embolic events compared with warfarin (moderate certainty).

1 finding from 1 review

Major bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).

1 finding from 1 review

Myocardial infarction · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in myocardial infarction compared with warfarin; GRADE not reported.

1 finding from 1 review

Minor bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in minor bleeding compared with warfarin (low certainty).

1 finding from 1 review

Gastrointestinal bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in gastrointestinal bleeding compared with warfarin (moderate certainty).

1 finding from 1 review

Intracranial haemorrhage · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) probably leads to lower intracranial haemorrhage compared with warfarin (moderate certainty).

1 finding from 1 review

All‐cause mortality · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).

1 finding from 1 review